Should You Buy Viking Therapeutics Before Nov. 5?

Viking Therapeutics (VKTX) is progressing its weight loss drug candidate, VK2735, with an injectable version in Phase 3 trials and an oral version in Phase 2, following promising Phase 2 data showing up to 13.1% average weight loss. The company aims to capture a share of the burgeoning obesity market, projected to reach $100 billion by 2030, currently dominated by Novo Nordisk and Eli Lilly. Despite a significant stock price drop over the past year, VKTX has seen a 16% rebound in the last three months, with upcoming medical conference presentations detailing Phase 3 study designs and VK2735's impact on metabolic conditions serving as potential catalysts.

Analysis

Viking Therapeutics (VKTX) is actively developing VK2735, a weight loss drug candidate, with an injectable version in Phase 3 trials and an oral version in Phase 2. This follows promising Phase 2 data demonstrating up to 13.1% average weight loss over 13 weeks without a plateau, positioning it within the high-growth GLP-1/dual GIP/GLP-1 agonist market. The obesity market is projected to reach $100 billion by 2030, indicating substantial opportunity despite competition from established players like Novo Nordisk and Eli Lilly.

VKTX shares have shown significant volatility, declining 47% over the past year from their peak, but have recently rebounded 16% over the last three months. This past decline was not attributed to adverse company news, but rather to factors such as profit-taking or investor disappointment regarding a lack of acquisition.

Upcoming catalysts include poster presentations at ObesityWeek 2025 and the American Heart Association Scientific Sessions 2025. These will detail VK2735's impact on prediabetes and metabolic syndrome, alongside Phase 3 study designs. While not expected to trigger massive stock movements, these presentations could reinforce optimism and highlight the drug's potential for broader health benefits, which is crucial for future reimbursement.

Key Decisions for Investors

• Monitor upcoming medical conference presentations for further validation of VK2735's broader health benefits and Phase 3 trial design, as these could provide incremental positive sentiment
• Evaluate VKTX's long-term potential in the rapidly expanding obesity market, considering its promising Phase 2 data and progression to Phase 3, despite strong competition from established players
• Consider building a position gradually, acknowledging the stock's recent rebound and the long development timeline for pharmaceutical assets, rather than expecting immediate, significant gains from near-term catalysts